Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
Clinical trial NCT02504216 · COMPLETED
Trial details
- NCT number
- NCT02504216
- Sponsor
- Bayer
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-08-18
- Primary completion
- 2019-11-27
- Enrollment
- 6564
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.